Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325859 | 0.85 | AMY1A (0.32) | MAPTNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL3321918 | 0.85 | GAA (0.36) | MAPTTDP1ALDH1A1 | |
| SCHEMBL968700 | 0.85 | KMT2A (0.33) | SMN1; SMN2RIPK1MAPTALDH1A1LMNA | |
| SCHEMBL13361923 | 0.80 | GRIN2D (0.37) | SMN1; SMN2MAPTNPC1ALDH1A1LMNA | |
| SCHEMBL12947965 | 0.76 | AGTR1 (0.30) | — | |
| SCHEMBL30954983 | 0.74 | S1PR4 (0.36) | SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL970413 | 0.73 | CRHR1 (0.36) | SMN1; SMN2MAPTNPC1ALDH1A1LMNA | |
| SCHEMBL3330603 | 0.73 | ALOX5 (0.33) | MAPTTDP1ALDH1A1LMNA | |
| SCHEMBL3324746 | 0.72 | PTGS2 (0.35) | ALDH1A1 | |
| SCHEMBL3326254 | 0.71 | CRHR1 (0.32) | SMN1; SMN2MAPTNPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2225248-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Wyeth LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010054260-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054260-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | SMN1; SMN2 1897/4885RIPK1 4445/4885MAPT 3773/4885 |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | PDE12, PDE5A, PDE10A | SMN1; SMN2 1586/4885RIPK1 4229/4885MAPT 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.